



Who we are

LEGATO unites European clinicians, researchers, health economists and patient representatives to improve treatment, survival and quality of life in recurrent glioblastoma.

What we are working on

A phase III trial compares lomustine plus reirradiation with lomustine alone, assessing effectiveness, safety, quality of life and cost-effectiveness.

What's the one thing we need next

We need to recruit 411 patients across around 40 sites to generate robust evidence on adding reirradiation to lomustine.



**5 years Mission Cancer:
Stronger Through Connection**

BRUSSELS

29 SEPTEMBER – 01 OCTOBER



For more info visit:
www.legato-horizon.eu



EUROPEAN UNION

LEGATO

